Antisense Therapeutics (ASX: ANP) Conducts Capital Raising Lead by Ethical Investment, Platinum Asset Management and CVC Limited

KEY TAKEAWAYS:

• Australian biopharmaceutical company Antisense Therapeutics has announced that its fund-raising campaign has been successful courtesy of support from multiple institutional investors.
• The aim to test the efficacy of the drug ATL1102 in treating DMD, an incurable disease that causes muscular wastage.
• Currently, this medical condition is known to affect 1 child in every 3600 children in Australia and Antisense will be holding trials at the neuromuscular facility of RCH,
  which also happens to be the biggest in the southern hemisphere.

Antisense Therapeutics, a well-know operator in Australia’s bio-pharmaceutical segment, announced that its fund-raising campaign had been a great success, thus enabling it to continue
with second phase of clinical trials in finding a cure for Duchenne Muscular Dystrophy. The company claims to have been supported by several institutional investors that operate in the
healthcare sector, like Australian Ethical Investment, CVC Limited, Platinum Asset Management and so on.

This capital raising exercise will follow a certain pre-defined pattern and is going to be managed by XEC Partners. Funds thus raised would be used to test the efficacy of ATL1102 through
Phase 2 trials on patients suffering from muscle wasting disease named DMD, which mostly affects children and is incurable so far. Depending on the report of this trial run, the company
will initiate a 3 rd phase wherein ATL1103 will be tested as an Early Access program.

To be able to commence a 6-month trial on patients, Antisense intends to seek permission from Royal Children’s Hospital to use its facility that happens to be the biggest in the southern
hemisphere for treating neuromuscular conditions. Enrollment of patients is expected to begin in May, 2018, with administering of doses to be completed by first quarter 2019, and study results
expected in the second quarter 2019.

DMD is an incurable muscular wastage disease that affects one child in every 3600 children in Australia, and has been found to occur due to specific gene mutation. Antisense is one of the first
companies to have come up with a therapeutic solution to the muscular inflammation caused by DMD.

About Antisense Therapeutics (ASX: ANP)

Antisense Therapeutics is an Australian publicly traded biopharmaceutical development company. The Company’s R&D activities are focused on developing and commercialising antisense drugs acquired from Ionis Pharmaceuticals Inc (NASDAQ:IONS), acknowledged world leaders in antisense drug development. The Company has an advanced stage product development pipeline with 2 compounds that have delivered positive Phase II clinical trial results.

Request Info